Francisco Chacón-Lozsán/LinkedIn
Mar 22, 2026, 14:46
Francisco Chacón-Lozsán: PE Is The New STEMI, But Are We Treating It Too Aggressively?
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared on LinkedIn:
”’PE is the new STEMI’ — but are we treating it too aggressively?
One of the most thought-provoking sessions at ACVC26 challenged the growing enthusiasm for catheter-directed therapies.
The message was clear:
- Not every PE needs intervention
- In fact, most patients do well with anticoagulation alone
- The real challenge is not how to treat – but who to treat.
Current risk scores don’t capture the full picture
More evidence is underway.
We need to move toward:
- Better understanding of RV failure
- Early identification of decompensation
- Truly individualized decision-making
Until then: Avoid ‘wild’ use of catheter-based therapies”
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 03:14Laura Girardi: A Survey Study on the Management of Incidental Pulmonary Embolism in Patients with Cancer
-
Apr 16, 2026, 03:10Folusho Adeosun: Your 30-Minute Plan for SCD Emergencies
-
Apr 16, 2026, 02:57Charlie Windri: CAC as the Missing Link in Lp(a) Risk
-
Apr 15, 2026, 21:27Satish Bondala: Blood Bank and Transfusion Services – The Lifeline of Hospitals
-
Apr 15, 2026, 21:26Tareq Abadl: Understanding Thalassemia – Breaking the ‘Ordinary Anemia’ Myth
-
Apr 15, 2026, 21:24Wolfgang Miesbach: Key Message from John Semple on Platelets as Immune Cells in ITP
-
Apr 15, 2026, 21:22Manuel Gutiérrez de Ravé: Promotion to Real-World Evidence Scientist at Terumo Blood and Cell Technologies
-
Apr 15, 2026, 18:45Elias Lee: Acute PE from Subclavian VT – CT Scan Diagnosis, Radiology Interpretation, and Emergency Imaging Insights
-
Apr 15, 2026, 17:30Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health